Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 3, 2026 21:25 UTC |
Bozic CarmenEVP and CMO
|
SaleCommon Stock | 2,329 | $480.31 | $1,118,641.99 |
DisclosureSEC source: 0000875320-26-000127 · wk-form4_1772573117.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,734 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 1,725 | $496.95 | $857,238.75 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 13 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,278 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F15 · price: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 5,995 | $496.16 | $2,974,479.20 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 12 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,003 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F14 · price: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 15,580 | $495.38 | $7,718,020.40 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 11 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,998 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13 · price: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 3,498 | $494.33 | $1,729,166.34 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 10 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,578 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 2,520 | $493.29 | $1,243,090.80 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 9 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,076 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 949 | $491.30 | $466,243.70 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 8 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,596 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 2,725 | $490.54 | $1,336,721.50 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,545 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 460 | $489.32 | $225,087.20 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,270 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 3,278 | $488.27 | $1,600,549.06 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,730 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 2,510 | $487.13 | $1,222,696.30 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,008 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 240 | $482.84 | $115,881.60 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,518 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 120 | $481.50 | $57,780.00 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,758 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 400 | $479.75 | $191,900.00 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,878 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76). Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:10 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 357 | $483.36 | $172,559.52 |
DisclosureSEC source: 0000875320-26-000125 · wk-form4_1772485797.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,624 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 22:56 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 223 | $486.35 | $108,456.05 |
DisclosureSEC source: 0000875320-26-000104 · wk-form4_1772146579.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,981 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:01 UTC |
Biller JonathanEVP and Chief Legal Officer
|
SaleCommon Stock | 945 | $486.35 | $459,600.75 |
DisclosureSEC source: 0000875320-26-000108 · wk-form4_1772146913.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,659 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:00 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
SaleCommon Stock | 668 | $486.35 | $324,881.80 |
DisclosureSEC source: 0000875320-26-000106 · wk-form4_1772146808.xml · nonDerivative · entry 2 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,432 F1 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:06 UTC |
Bunnage Mark E.EVP, Chief Scientific Officer
|
SaleCommon Stock | 620 | $486.35 | $301,537.00 |
DisclosureSEC source: 0000875320-26-000112 · wk-form4_1772147216.xml · nonDerivative · entry 2 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,284 F1 · kind: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:48 UTC |
McKechnie DuncanEVP, Chief Commercial Officer
|
SaleCommon Stock | 2,410 | $489.00 | $1,178,490.00 |
DisclosureSEC source: 0000875320-26-000116 · wk-form4_1772149699.xml · nonDerivative · entry 3 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,559 F1 · kind: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:48 UTC |
McKechnie DuncanEVP, Chief Commercial Officer
|
SaleCommon Stock | 2,500 | $486.35 | $1,215,875.00 |
DisclosureSEC source: 0000875320-26-000116 · wk-form4_1772149699.xml · nonDerivative · entry 2 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,969 F1 · kind: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:50 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 1,846 | $486.35 | $897,802.10 |
DisclosureSEC source: 0000875320-26-000118 · wk-form4_1772149844.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,570 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:55 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 260 | $486.35 | $126,451.00 |
DisclosureSEC source: 0000875320-26-000120 · wk-form4_1772150109.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,763 F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 546 | $485.11 | $264,870.06 |
DisclosureSEC source: 0000875320-26-000104 · wk-form4_1772146579.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,204 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:01 UTC |
Biller JonathanEVP and Chief Legal Officer
|
Tax withholdingCommon Stock | 1,144 | $485.11 | $554,965.84 |
DisclosureSEC source: 0000875320-26-000108 · wk-form4_1772146913.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,604 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:00 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
Tax withholdingCommon Stock | 1,627 | $485.11 | $789,273.97 |
DisclosureSEC source: 0000875320-26-000106 · wk-form4_1772146808.xml · nonDerivative · entry 1 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,100 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:05 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 1,453 | $485.11 | $704,864.83 |
DisclosureSEC source: 0000875320-26-000110 · wk-form4_1772147118.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,063 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:06 UTC |
Bunnage Mark E.EVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 582 | $485.11 | $282,334.02 |
DisclosureSEC source: 0000875320-26-000112 · wk-form4_1772147216.xml · nonDerivative · entry 1 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,904 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:48 UTC |
McKechnie DuncanEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 873 | $485.11 | $423,501.03 |
DisclosureSEC source: 0000875320-26-000116 · wk-form4_1772149699.xml · nonDerivative · entry 1 McKechnie Duncan · CIK 0002062139 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,469 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:09 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 4,981 | $485.11 | $2,416,332.91 |
DisclosureSEC source: 0000875320-26-000114 · wk-form4_1772147388.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,278 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:50 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Tax withholdingCommon Stock | 1,518 | $485.11 | $736,396.98 |
DisclosureSEC source: 0000875320-26-000118 · wk-form4_1772149844.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,416 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:55 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 1,627 | $485.11 | $789,273.97 |
DisclosureSEC source: 0000875320-26-000120 · wk-form4_1772150109.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,023 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:56 UTC |
WAGNER CHARLES F JREVP, CO & FO
|
Tax withholdingCommon Stock | 1,744 | $485.11 | $846,031.84 |
DisclosureSEC source: 0000875320-26-000122 · wk-form4_1772150196.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP, CO & FO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,042 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:11 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 3,547 | $485.11 | $1,720,685.17 |
DisclosureSEC source: 0001242825-26-000002 · wk-form4_1772147464.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,797 Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,026 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · derivative · entry 14 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,026 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 23,479 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · derivative · entry 13 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,479 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 4,237 | $471.43 | $1,997,448.91 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,934 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $471.43 (range $471.10 to $472.03). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 11,712 | $470.54 | $5,510,964.48 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,171 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $470.54 (range $470.10 to $471.08). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 7,241 | $469.61 | $3,400,446.01 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,883 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $469.61 (range $469.10 to $470.05). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 19,662 | $468.57 | $9,213,023.34 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,124 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $468.57 (range $468.10 to $469.09). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 10,263 | $467.75 | $4,800,518.25 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,786 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $467.75 (range $467.09 to $468.05). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 1,848 | $465.80 | $860,798.40 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,049 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $465.80 (range $465.54 to $466.49). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 2,730 | $465.05 | $1,269,586.50 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,897 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $465.05 (range $464.48 to $465.46). Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
SaleCommon Stock | 920 | $463.91 | $426,797.20 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,627 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025. F2 · price: Open market sales reported on this line occurred at a weighted average price of $463.91 (range $463.44 to $464.28). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Exercise / conversionCommon Stock | 25,026 | $187.53 | $4,693,125.78 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:21 UTC |
Sachdev AmitEVP Chief Patient & Ext Af Off
|
Exercise / conversionCommon Stock | 23,479 | $155.57 | $3,652,628.03 |
DisclosureSEC source: 0000875320-26-000102 · wk-form4_1771881700.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:03 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 638 | $473.68 | $302,207.84 |
DisclosureSEC source: 0000875320-26-000080 · wk-form4_1771535003.xml · nonDerivative · entry 4 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,750 F2 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:06 UTC |
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.
|
SaleCommon Stock | 817 | $473.68 | $386,996.56 |
DisclosureSEC source: 0000875320-26-000082 · wk-form4_1771535181.xml · nonDerivative · entry 4 Atkinson Edward Morrow III · CIK 0001914164 · EVP, Chief Technical Ops. Off. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,727 F2 · kind: Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:08 UTC |
Biller JonathanEVP and Chief Legal Officer
|
SaleCommon Stock | 1,244 | $473.68 | $589,257.92 |
DisclosureSEC source: 0000875320-26-000084 · wk-form4_1771535316.xml · nonDerivative · entry 4 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,748 F2 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:12 UTC |
Bunnage Mark E.EVP, Chief Scientific Officer
|
SaleCommon Stock | 1,182 | $473.68 | $559,889.76 |
DisclosureSEC source: 0000875320-26-000088 · wk-form4_1771535561.xml · nonDerivative · entry 4 Bunnage Mark E. · CIK 0002100735 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,486 F2 · kind: Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.